On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Denbury Resources (NYSE:DNR), Olin (NYSE:OLN), Veeva Systems (NYSE:VEEV), Nektar Therapeutics (NASDAQ:NKTR)
Denbury Resources Inc. (NYSE:DNR) fell -3.49%, and closed at $7.20. The stock has the beta value of 2.11, and its volatility for the week is 6.96%, while for the month it is 5.24%. The company has the market capitalization of $2.66 Billion. The company holds the book value per share of 16.35, whereas cash per share is 0.07. Price to book ratio remained 0.44, while price to sale ratio is 1.05. Analysts mean recommendation for the stock is said to be 2.80 (where 1=Buy, 5=sale).
Denbury Resources Inc. (DNR) operates as an independent oil and natural gas company in the United States. The company primarily focuses on enhanced oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region. As of December 31, 2014, it had 437.7 million barrels of oil equivalent of estimated proved oil and natural gas reserves. The company was founded in 1951 and is headquartered in Plano, Texas.
Olin Corporation (NYSE:OLN) decreased -3.42%, and closed at $28.25. The stock has price to sale ratio of 0.98, however, price to book ratio is 2.17. With recent decline, the year-to-date (YTD) performance reflected a 21.61% incline above last year. During the past month the stock gain 1.07%, bringing three-month performance to 24.61% and six-month performance to 9.07%. The mean recommendation of analysts for this stock is 2.70 (where 1=Buy, 5=Sale).
Olin Corporation (OLN) manufactures and sells chlor alkali products in the United States and internationally. The company operates through three segments: Chlor Alkali Products, Chemical Distribution, and Winchester. The Chlor Alkali Products segment provides chlorine/caustic soda that is used in pulp and paper processing, chemical manufacturing, and water purification, as well as in the manufacture of vinyl chloride, bleach, swimming pool chemicals, and urethane chemicals; sodium hypochlorite for use in household cleaners, laundry bleaching, swimming pool sanitizers, semiconductors, water treatment, textile, pulp and paper, and food processing; and hydrogen used in fuel source, hydrogen peroxide, and hydrochloric acid.
Veeva Systems Inc (NYSE:VEEV) declined -3.34%, and closed at $26.37. The company has the market capitalization of $3.56 billion. On the other hand the stock’s volatility for the week is 4.34%, and for the month is 4.18%. The stock’s price to book ratio is $8.45, however price to sale ratio is $11.00. Analyst’s mean recommendation regarding this stock is 1.80. (Where 1=Buy, 5=Sale).
Veeva Systems Inc (VEEV) provides industry-specific cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America. The companys solutions enable pharmaceutical and other life sciences companies to realize the benefits of cloud-based architectures and mobile applications for various business functions.
Nektar Therapeutics (NASDAQ:NKTR) shares picked down -3.33%, and closed at $11.62. The stock volatility for the week is 6.23%, while for the month remained 4.98%. The company holds consensus target price of $15.42.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.45 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 70.00% and Annual EPS growth for the past 5 years is considered as 17.70%.
The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).
Nektar Therapeutics (NKTR) a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
